The lancet oncology
-
The lancet oncology · Apr 2021
Randomized Controlled Trial Multicenter StudyAdjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Despite standard curative-intent treatment with neoadjuvant cisplatin-based chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial carcinoma has a high recurrence rate and no level 1 evidence for adjuvant therapy. We aimed to evaluate atezolizumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma. ⋯ F Hoffmann-La Roche/Genentech.
-
The lancet oncology · Apr 2021
Meta AnalysisAntihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Some studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in a large individual patient data meta-analysis of randomised clinical trials. ⋯ British Heart Foundation, National Institute for Health Research, Oxford Martin School.
-
The lancet oncology · Apr 2021
Randomized Controlled Trial Multicenter StudySecondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population. ⋯ For the Chinese translation of the abstract see Supplementary Materials section.
-
The lancet oncology · Apr 2021
Randomized Controlled Trial Multicenter StudyAvelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population. ⋯ Pfizer and Merck KGaA, Darmstadt, Germany.